CW
Chefs' Warehouse, Inc. (CHEF)·Q3 2025 Earnings Summary
Executive Summary
- Q3 2025 delivered solid top-line growth and non-GAAP profitability: net sales up 9.6% YoY to $1.021B, adjusted EPS $0.50 and adjusted EBITDA $65.1M .
- Versus S&P Global consensus, CHEF beat on revenue ($1.021B vs $0.986B*) and EPS ($0.50 vs $0.416*), while EBITDA was modestly below S&P’s EBITDA consensus ($58.7M actual vs $59.6M*) .
- Mix was constructive in specialty (gross margin +59 bps YoY), while center‑of‑the‑plate margins compressed (‑49 bps); adjusted FY25 guidance was raised across revenue, gross profit and adjusted EBITDA .
- Management flagged healthy demand into October and a “cautiously optimistic” 4Q setup; acquisition of Italco expands into Colorado; Middle East remains a growth engine despite temporary summer headwinds in Qatar .
Note: *Values retrieved from S&P Global.
What Went Well and What Went Wrong
-
What Went Well
- Revenue and profitability momentum: net sales +9.6% YoY to $1,021.3M; adjusted EPS $0.50 vs $0.36 YoY; adjusted EBITDA $65.1M vs $54.5M YoY .
- Specialty category execution: specialty margins +59 bps YoY; placements +5.3% and unique customers +2.6% YoY in Q3; excluding Texas processing exit, specialty cases +5.4% .
- Healthy demand and share gains: “momentum in demand and market share gains continued into October” with multiple regions growing and double‑digit growth in several high‑growth markets . Quote: “We… started to invest in the facilities… sales force… technology… the team is… gaining market share and winning in a lot of categories” .
-
What Went Wrong
- Center‑of‑the‑plate margin pressure: category margins ‑49 bps YoY amid elevated protein inflation (beef) and pricing lag effects; strategy is to hold price longer on the way down to recover over time .
- Reported volume optics from Texas program exits: center‑of‑the‑plate pounds ‑1.1% reported, though +9.6% excluding commodity poultry attrition; reported unique customer growth damped by Texas exits and temporary Middle East conflict impact .
- Sequential softening vs Q2: revenue slipped from $1,034.9M to $1,021.3M; gross margin moderated from 24.6% to 24.2% .
Financial Results
Headline P&L (GAAP/Non‑GAAP) – Last 3 Quarters
YoY reference for Q3: revenue $931.5M and GAAP EPS $0.34 in Q3’24; adjusted EPS $0.36; adjusted EBITDA $54.5M .
Q3 2025: Actuals vs S&P Global Consensus
Note: *Values retrieved from S&P Global.
Segment & Operating KPIs
Guidance Changes
Management added that at the midpoint, 4Q implies ~7%–7.5% revenue growth and ~10% flow‑through to adjusted EBITDA, reflecting typical conservatism and tougher comps .
Earnings Call Themes & Trends
Management Commentary
- Strategic focus: “Our operating divisions… delivered strong growth in revenue and gross profit dollars… momentum in demand and market share gains continued into October” .
- On Q4 and guidance tone: “We feel pretty good about the mid to higher end of the guidance… we’re always a little… conservative” .
- On protein inflation/margins: “Protein prices have been pretty firm… year‑over‑year protein margins were down… we got really good gross profit dollar growth… you’re not going to pass all of it on” .
- On digital/AI: “We’re a little bit over 60% [digital adoption]… we’re using AI and investing in AI… but the differentiator… is customer service” .
- On competitive consolidation: Large distributor combinations can create customer hedging and talent opportunities—“we usually get a nice uptick” .
Q&A Highlights
- Demand cadence: Summer was solid across July–Sept; momentum continued into October; 4Q expected to perform “pretty well” .
- Margin model: Specialty margins +59 bps YoY; protein pressure managed via pricing cadence and supply-chain execution .
- Texas transformation: Shedding non-core, low-margin programs; rebuilding routes with CW‑profile accounts; in “second inning” with significant runway .
- Tariffs/Inflation: Tariff impacts partly offset by substitution and category diversity; net underlying inflation (ex program exits) ~2–3% modeled earlier in the year .
- Middle East: Temporary Qatar disruption in summer; facilities expanded in Dubai/Qatar/Oman; aggregate region in double‑digit growth .
Estimates Context
- Q3 2025 outcomes vs S&P Global consensus: Revenue beat ($1,021.3M vs $985.96M*), EPS beat ($0.50 vs $0.416*), EBITDA slightly below ($58.7M vs $59.6M*) .
- Prior quarters also exceeded on revenue and EPS vs S&P consensus (Q2: $1,034.9M vs $1,013.5M*; $0.52 vs $0.461*; Q1: $950.7M vs $926.6M*; $0.25 vs $0.195*) .
- Guidance raises (sales, gross profit, adj. EBITDA) suggest upward pressure on FY25 sell‑side models, while category mix and protein margin recovery cadence may shape 4Q profitability expectations .
Note: *Values retrieved from S&P Global.
Key Takeaways for Investors
- Revenue and adjusted EPS beats, plus a full‑year guidance raise across all key metrics, reinforce an improving operating backdrop and execution momentum .
- Mix dynamics remain favorable: specialty strength and placements growth, with protein margins managed through pricing cadence; expect margin normalization as inflation moderates .
- Reported volume optics (Texas attrition) mask underlying growth in center‑of‑the‑plate pounds; excluding exits, growth is strong and capacity is being refilled with higher‑quality CW accounts .
- Digital adoption exceeds 60% and AI initiatives enhance efficiency; management emphasizes customer service as the sustainable differentiator .
- Middle East continues to provide a durable growth vector despite episodic disruptions; US demand appears resilient into the holiday period .
- Near‑term trading: Positive surprise on revenue/EPS and raised FY guide are likely constructive catalysts; modest sequential gross margin easing and protein margin pressure are watch‑items .
- Medium‑term thesis: Operating leverage, route/employee productivity, disciplined tuck‑ins (e.g., Italco), and continued CW‑model expansion into new markets support the 2028 margin roadmap .
Sources
- Q3 2025 8‑K and press release: revenue, margins, EPS, adjusted metrics, and FY25 guidance .
- Q3 2025 earnings call transcript: demand/mix commentary, digital/AI, Middle East, Texas, and Q&A .
- Q2 2025 8‑K and call: comps, guidance baseline, specialty/protein metrics, inflation .
- Q1 2025 8‑K and call: early‑year run‑rate, digital baseline, tariff context .
Note: S&P Global consensus figures marked with an asterisk (*) are values retrieved from S&P Global.